Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 377

1.

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.

Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT.

J Neurol. 2014 Jul 3. [Epub ahead of print]

PMID:
24989666
[PubMed - as supplied by publisher]
2.

Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.

Lukas C, Knol DL, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Weier K, Radue EW, Gass A, Kappos L, Naegelin Y, Uitdehaag BM, Geurts JJ, Barkhof F, Vrenken H.

J Neurol Neurosurg Psychiatry. 2014 Jun 27. pii: jnnp-2014-308021. doi: 10.1136/jnnp-2014-308021. [Epub ahead of print]

PMID:
24973341
[PubMed - as supplied by publisher]
3.

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW.

J Neurol. 2014 Jun 28. [Epub ahead of print]

PMID:
24972678
[PubMed - as supplied by publisher]
4.

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.

Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu CH, Dobson R, Disanto G, Norgren N, Nissim A, Kappos L, Hurlbert J, Yong VW, Giovannoni G, Casha S.

J Neurol Neurosurg Psychiatry. 2014 Jun 16. pii: jnnp-2013-307454. doi: 10.1136/jnnp-2013-307454. [Epub ahead of print]

PMID:
24935984
[PubMed - as supplied by publisher]
5.

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

J Immunol Res. 2014;2014:897249. doi: 10.1155/2014/897249. Epub 2014 May 12.

PMID:
24901013
[PubMed - in process]
Free PMC Article
6.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4.

PMID:
24898925
[PubMed - indexed for MEDLINE]
7.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

PMID:
24871874
[PubMed - in process]
Free PMC Article
8.

Determinants of iron accumulation in deep grey matter of multiple sclerosis patients.

Ropele S, Kilsdonk ID, Wattjes MP, Langkammer C, de Graaf WL, Frederiksen JL, Larsson HB, Yiannakas M, Wheeler-Kingshott CA, Enzinger C, Khalil M, Rocca MA, Sprenger T, Amann M, Kappos L, Filippi M, Rovira A, Ciccarelli O, Barkhof F, Fazekas F.

Mult Scler. 2014 Apr 30. [Epub ahead of print]

PMID:
24787429
[PubMed - as supplied by publisher]
9.

Multiple sclerosis registries in Europe - results of a systematic survey.

Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, Confavreux C, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Orologas A, Otero-Romero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Yaldizli O.

Mult Scler. 2014 Apr 28. pii: 1352458514528760. [Epub ahead of print] No abstract available.

PMID:
24777278
[PubMed - as supplied by publisher]
10.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
[PubMed - indexed for MEDLINE]
11.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P.

Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28.

PMID:
24682966
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Oral disease modifying therapy of multiple sclerosis: the current view.]

Kappos L, Boĭko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(2 Vypusk 2 Rasseiannyi skleroz):63-71. Russian.

PMID:
24662359
[PubMed - as supplied by publisher]
13.

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group.

Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6.

PMID:
24613349
[PubMed - indexed for MEDLINE]
14.

MiR-126: a novel route for natalizumab action?

Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RL.

Mult Scler. 2014 Sep;20(10):1363-1370. Epub 2014 Mar 5.

PMID:
24598267
[PubMed - as supplied by publisher]
15.

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.

Schlaeger R, Schindler C, Grize L, Dellas S, Radue EW, Kappos L, Fuhr P.

Mult Scler. 2014 Sep;20(10):1348-1354. Epub 2014 Feb 26.

PMID:
24574192
[PubMed - as supplied by publisher]
16.

Prediction of MS disability by multimodal evoked potentials: Investigation during relapse or in the relapse-free interval?

Schlaeger R, D'Souza M, Schindler C, Grize L, Kappos L, Fuhr P.

Clin Neurophysiol. 2014 Sep;125(9):1889-92. doi: 10.1016/j.clinph.2013.12.117. Epub 2014 Jan 31.

PMID:
24555924
[PubMed - in process]
17.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; on behalf of the TYSABRI Observational Program (TOP) Investigators.

J Neurol Neurosurg Psychiatry. 2014 Feb 14. doi: 10.1136/jnnp-2013-306936. [Epub ahead of print]

PMID:
24532785
[PubMed - as supplied by publisher]
Free Article
18.

Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability.

Magon S, Chakravarty MM, Amann M, Weier K, Naegelin Y, Andelova M, Radue EW, Stippich C, Lerch JP, Kappos L, Sprenger T.

Hum Brain Mapp. 2014 Aug;35(8):4193-203. doi: 10.1002/hbm.22470. Epub 2014 Feb 7.

PMID:
24510715
[PubMed - in process]
19.

Clinical trials in multiple sclerosis.

Cutter G, Kappos L.

Handb Clin Neurol. 2014;122:445-53. doi: 10.1016/B978-0-444-52001-2.00019-4.

PMID:
24507530
[PubMed - in process]
20.

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.

Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, Donati F, Müller M, Müller F, Slotboom J, Kappos L, Naegelin Y, Mattle HP; SWABIMS Study Group.

PLoS One. 2014 Jan 30;9(1):e86663. doi: 10.1371/journal.pone.0086663. eCollection 2014.

PMID:
24497963
[PubMed - in process]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk